(-1.36%) 5 002.81 points
(-1.77%) 37 782 points
(-1.72%) 15 443 points
(-0.60%) $82.31
(-2.00%) $1.620
(0.81%) $2 357.30
(0.87%) $27.59
(0.49%) $920.30
(-0.13%) $0.933
(0.03%) $10.99
(-0.28%) $0.800
(-0.30%) $92.04
-1.90% KRW 9 790.00
Live Chart Being Loaded With Signals
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors...
Stats | |
---|---|
Today's Volume | 239 892 |
Average Volume | 1.18M |
Market Cap | 328.76B |
EPS | KRW0 ( 2024-03-13 ) |
Next earnings date | ( KRW0 ) 2024-05-10 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW9.38 (0.10%) |
Volume Correlation
MedPacto, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
MedPacto, Inc. Correlation - Currency/Commodity
MedPacto, Inc. Financials
Annual | 2023 |
Revenue: | KRW0 |
Gross Profit: | KRW-1.83B (0.00 %) |
EPS: | KRW-1 664.87 |
Q4 | 2023 |
Revenue: | KRW0 |
Gross Profit: | KRW-421.64M (0.00 %) |
EPS: | KRW-349.31 |
Q3 | 2023 |
Revenue: | KRW0 |
Gross Profit: | KRW-462.95M (0.00 %) |
EPS: | KRW-251.05 |
Q2 | 2023 |
Revenue: | KRW0 |
Gross Profit: | KRW-473.85M (0.00 %) |
EPS: | KRW-306.34 |
Financial Reports:
No articles found.
MedPacto, Inc.
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators